Bio-Techne price target raised to $83 from $80 at Scotiabank

Scotiabank raised the firm’s price target on Bio-Techne to $83 from $80 and keeps an Outperform rating on the shares. The company’s Q3 results beat expectations, with key drivers including stabilization across biopharma and China end markets as well as strong double-digit growth across Cell & Gene Therapy, Molecular Diagnostics, and Spatial Biology portfolios, the analyst tells investors.